Literature DB >> 11673755

Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.

R Brandolese1, M G Scordo, E Spina, M Gusella, R Padrini.   

Abstract

A 31-year-old woman who had a severe head injury was treated with oral phenytoin (100 mg 3 times a day) to prevent posttraumatic seizures. On day 10 of phenytoin treatment, 3 hours after the morning dose, the patient manifested neurologic signs compatible with phenytoin intoxication. Thus drug serum concentrations were monitored daily for 12 days. The elimination half-life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours). In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CYP) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected. Genotyping revealed that the patient was homozygous for the CYP2C9*3 allele (CYP2C9*3/*3) and heterozygous for the CYP2C19*2 allele (CYP2C19*1/*2). In view of the markedly reduced metabolic activity of CYP2C*3 in comparison with the wild-type enzyme (about one fifth) and of the minor role of CYP2C19 in phenytoin metabolism, it is likely that CYP2C9*3 mutation was largely responsible for drug overdose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673755

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.

Authors:  Umit Yasar; Marja-Liisa Dahl; Magnus Christensen; Erik Eliasson
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis.

Authors:  Sergi Mas; Anna Crescenti; Jose M Vidal-Taboada; Salvador Bergoñon; Fernando Cuevillas; Nuria Laso; Rafael Molina; Antonio Ballesta; Amalia Lafuente
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

Review 5.  Phenytoin poisoning.

Authors:  Simon Craig
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 6.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2011-02-11

Review 7.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

9.  CYP2C9 genetic variants and losartan oxidation in a Turkish population.

Authors:  Melih O Babaoglu; Umit Yasar; Mia Sandberg; Erik Eliasson; Marja-Liisa Dahl; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

10.  Noncompliance leading to drug accumulation resulting in phenytoin toxicity.

Authors:  Ravi Akula; Syed Hasan; Rao Pipalla; Clifford Ferguson
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.